Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA147433 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Human Peripheral blood mononuclear cells (PBMCs): Control vs. Kashin-Beck Disease
| PRJNA255333 | ENA
Project description:Objective: To investigate the differences between the gene expression profiles in peripheral blood mononuclear cells (PBMC) from normal controls and patients with Kashin-Beck disease (KBD). Methods: Twenty KBD patients and 12 normal subjects were selected from a KBD-endemic area and divided into four pairs of KBD vs. control (KBD, n=5 per pair; control, n=3 per pair). RNAs were respectively isolated from KBD PBMCs and normal PBMCs. Gene expression profiles were analyzed by oligonucleotide microarray.
2011-09-23 | GSE32127 | GEO
Project description:Objective: To investigate the differences between the gene expression profiles in peripheral blood mononuclear cells (PBMC) from normal controls and patients with Kashin-Beck disease (KBD). Methods: Twenty KBD patients and 12 normal subjects were selected from a KBD-endemic area and divided into four pairs of KBD vs. control (KBD, n=5 per pair; control, n=3 per pair). RNAs were respectively isolated from KBD PBMCs and normal PBMCs. Gene expression profiles were analyzed by oligonucleotide microarray. Two-condition experiment, control vs. KBD PBM cells. Biological replicates: 4 control replicates, 4 KBD replicates.
2011-09-22 | E-GEOD-32127 | biostudies-arrayexpress
Project description:Objective:To identify an accurate blood-based gene signature for early detection of Kashin-Beck disease (KBD). Methods: Gene expression analysis was conducted of peripheral blood samples from 100 patients with KBD and 100 controls randomly chosen from two KBD-endemic areas Two-condition experiment, Control vs. KBD PBM cells. Biological replicates: 100 control replicates, 100 KBD replicates.
2014-07-16 | E-GEOD-59446 | biostudies-arrayexpress
Project description:Kashin-Beck disease (KBD) is an endemic and chronic osteochondropathy with unknown etiology. The disease mostly occurs in children between the ages of 3 and 13 in a diagonal belt-like area ranging from Northeast to Southwest China. We carried out this microarray analysis to investigate the differences in gene expression levels between KBD patients and healthy controls. Total RNA was isolated from peripheral blood mononuclear cells (PBMCs).
2014-08-30 | E-MTAB-2494 | biostudies-arrayexpress
Project description:Objective:To identify an accurate blood-based gene signature for early detection of Kashin-Beck disease (KBD). Methods: Gene expression analysis was conducted of peripheral blood samples from 100 patients with KBD and 100 controls randomly chosen from two KBD-endemic areas
2014-07-16 | GSE59446 | GEO
Project description:Expression data from heart failure vs control peripheral blood mononuclear cells.
| PRJNA102667 | ENA
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO
Project description:Alzheimer Disease peripheral blood mononuclear cell expression
| PRJNA94873 | ENA
Project description:Transcriptomic profiling of peripheral blood mononuclear cells from patients with Parkinson’s disease and control subjects.
| PRJNA128683 | ENA